Li et al (Ma et al., 2022) demonstrated, for the first time, that low molecular weight heparin (LMWH) can reduce plasma LAC levels in patients with COVID-19, which may be associated with a reduction of microthrombus formation. This evidence concerns the gene LCT and COVID-19.